

### EMORY UNIVERSITY SCHOOL OF MEDICINE

Department of Pathology and Laboratory Medicine







Department of Pathology and Laboratory Medicine




# 46 year-old female with adnominal mass


## Linsheng Zhang, MD, PhD **Disclosure**

No conflict of interest to disclose

#### Clinical history


- 46 year-old female with abdominal pain
- Untrasound of abdomen found a small mass
- Confirmed by MRI: a well circumscribed T2
  hyperintense mass, 2.5 x 4.2 cm, cranial to an
  abutting junction of the pancreatic body and tail.
- Mass was resected (virtual slide).








The specimen is entirely submitted for histology exam.


Maximum size of the nodule: 7.5 mm































#### Flow Cytometry




Mature lymphocytes>97%. T-cells show no aberrant phenotype; B-cells are polytypic.

#### Differential Diagnosis

- Follicular dendritic cell sarcoma
- Interdigitating dendritic cell sarcoma
- Intranodal palisaded myofibroblastoma (prominent hemorrhage, amianthoid fibers)
- Inflammatory myofibroblastic tumor
- Angiomatoid fibrous histiocytoma (Circumscribed, fibrous pseudocapsule)
- Lymphoepithelioma-like carcinoma
- Metastatic malignancies:
  - Melanoma
  - Spindle cell carcinoma
  - Gastrointestinal stromal tumor (GIST).
  - Malignant peripheral nerve sheath tumors






# **CD30**


#### CD21







#### CD35








D2-40











#### Follicular Dendritic Cell Sarcoma

- Uncommon neoplastic proliferation of spindled to ovoid cells.
- Most FDCS arisen from lymph nodes, at least one-third occur in extranodal sites.
- At least some morphologic features of normal FDCs.
- A broad differential diagnosis: spindle cell proliferation/neoplasm
- Characteristic immunophenotypic profile.
  - Relatively specific (may have partial loss): CD21, CD23, CD35, clusterin
  - Sensitive but not specific: D2-40, Fascin
  - Misleading markers (variably positive): CD68, S100, EMA
- Ki-67 usually low, 1-25%
- ~20% harbors BRAF V600E mutation

#### Some Clinical Associations

- Castleman disease
- Angioimmunlblastic T-cell lymphoma (AITL)
- Follicular lymphoma
- Dysregulated immune system:
  - Paraneoplastic pemphigus
  - Myasthenia gravis

#### Prognosis of FDCS

- Local recurrences are common, occurring in approximately 40% to 50% of cases.
- Common metastatic sites: liver, lung, and lymph nodes.
- The mortality rate is approximately 20%, usually after a protracted course.

#### Prognostic Factors of FDCS

- Tumors arising in lymph nodes are often indolent, with low rate of metastases (approximately 10%).
- Unfavorable prognostic factors:
  - intra-abdominal location,
  - large tumor size (greater than 6 cm)
  - Coagulative necrosis,
  - mitotic count greater than 5 mitoses per 10 highpower fields,
  - Significant cellular atypia
- Intraabdominal location is the single most important unfavorable prognostic (relapse rate as high as 80%).

#### Follow up 4 years later

No clinical presentation;

No new adenopathy.